Maria Eugenia Quiros Roldan

List of Publications by Year
in descending order

139 papers	7,538 citations	159358 30 h-index	62479 80 g-index
148 all docs	148 docs citations	148 times ranked	12855 citing authors

#	Article	IF	Citations
1	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,983
2	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,749
3	Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infectious Diseases, The, 2013, 13, 927-935.	4.6	333
4	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet, The, 2004, 364, 51-62.	6.3	303
5	Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy. Kidney International Reports, 2020, 5, 580-585.	0.4	195
6	Mortality for Liver Disease in Patients With HIV Infection: A Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 211-217.	0.9	190
7	Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. ELife, 2021, 10, .	2.8	145
8	Severe Hepatotoxicity During Combination Antiretroviral Treatment: Incidence, Liver Histology, and Outcome. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 32, 259-267.	0.9	115
9	Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection. Clinical Infectious Diseases, 2011, 52, 1164-1173.	2.9	70
10	Incidence of <scp>AIDS</scp>â€defining cancers and virusâ€related and nonâ€virusâ€related nonâ€<scp>AIDS</scp>â€defining cancers among <scp>HIV</scp>â€infected patients compared with the general population in a large health district of northern <scp>I</scp>taly, 1999â€“2009. HIV Medicine, 2013, 14, 481-490.	1.0	66
11	Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. Clinical Microbiology and Infection, 2012, 18, 449-458.	2.8	61
12	Real Versus Virtual Phenotype to Guide Treatment in Heavily Pretreated Patients: 48-Week Follow-Up of the Genotipo-Fenotipo di Resistenza (GenPheRex) Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 32, 268-280.	0.9	60
13	Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS ONE, 2017, 12, e0186638.	1.1	59
14	Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time. PLoS ONE, 2010, 5, e11505.	1.1	56
15	Comparison between Rulesâ€Based Human Immunodeficiency Virus Type 1 Genotype Interpretations and Real or Virtual Phenotype: Concordance Analysis and Correlation with Clinical Outcome in Heavily Treated Patients. Journal of Infectious Diseases, 2003, 188, 194-201.	1.9	53
16	Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. EBioMedicine, 2021, 65, 103246.	2.7	52
17	Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study. PLoS ONE, 2014, 9, e94768.	1.1	50
18	A Randomized Controlled Trial to Evaluate Antiretroviral Salvage Therapy Guided by Rules-Based or Phenotype-Driven HIV-1 Genotypic Drug-Resistance Interpretation With or Without Concentration-Controlled Intervention: The Resistance and Dosage Adapted Regimens (RADAR) Study. Clinical Infectious Diseases, 2005, 40, 1828-1836.	2.9	49

#	Article	IF	Citations
19	Consequences of the COVID-19 pandemic on the continuum of care in a cohort of people living with HIV followed in a single center of Northern Italy. AIDS Research and Therapy, 2020, 17, 59.	0.7	49
20	Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review. International Journal of Molecular Sciences, 2022, 23, 1987.	1.8	48
21	Late Presenters in New HIV Diagnoses from An Italian Cohort of HIV-Infected Patients: Prevalence and Clinical Outcome. Antiviral Therapy, 2011, 16, 1103-1112.	0.6	45
22	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clinical Infectious Diseases, 2017, 65, 1316-1326.	2.9	44
23	Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients. Annals of Internal Medicine, 2017, 166, 9.	2.0	41
24	Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment. Biomedical Journal, 2021, 44, 43-53.	1.4	41
25	Risk of Early Virological Failure of Onceâ€Daily Tenofovirâ€Emtricitabine plus Twiceâ€Daily Nevirapine in Antiretroviral Therapyâ€“Naive HIVâ€Infected Patients. Clinical Infectious Diseases, 2008, 46, 1127-1129.	2.9	39
26	A Randomized, Pilot Trial to Evaluate Glomerular Filtration Rate by Creatinine or Cystatin C in Naive HIV-Infected Patients After Tenofovir/Emtricitabine in Combination With Atazanavir/Ritonavir or Efavirenz. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 18-24.	0.9	37
27	Cervical cancer risk in women living with HIV across four continents: A multicohort study. International Journal of Cancer, 2020, 146, 601-609.	2.3	37
28	Burden of Non-AIDS-Defining and Non-Virus-Related Cancers Among HIV-Infected Patients in the Combined Antiretroviral Therapy Era. AIDS Research and Human Retroviruses, 2013, 29, 1097-1104.	0.5	34
29	Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. Pharmaceuticals, 2021, 14, 454.	1.7	34
30	Bcl-2 expression is moderately correlated with long-term variability of CD4 T-cell increase under successful highly active antiretroviral therapy. Aids, 2003, 17, 141-143.	1.0	33
31	Increasing Clinical Virulence in Two Decades of the Italian HIV Epidemic. PLoS Pathogens, 2009, 5, e1000454.	2.1	33
32	Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infectious Diseases, 2012, 12, 38.	1.3	33
33	Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 1551-1558.	0.6	30
34	Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infectious Diseases, 2005, 5, 58.	1.3	29
35	Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study. BMC Public Health, 2015, 15, 235.	1.2	29
36	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 1955-1964.	1.3	29

#	Article	IF	Citations
37	Clinical Characteristics, Incidence, and Risk Factors of HIV-Related Hodgkin Lymphoma in the Era of Combination Antiretroviral Therapy. AIDS Patient Care and STDs, 2013, 27, 259-265.	1.1	28
38	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. Journal of Antimicrobial Chemotherapy, 2017, 72, 2055-2059.	1.3	28
39	Assessment of T-Cell receptor Î²-chain diversity by heteroduplex analysis. Human Immunology, 1996, 48, 12-22.	1.2	26
40	Prevalence and Risk Factors for Etravirine Resistance among Patients Failing on Non-Nucleoside Reverse Transcriptase Inhibitors. Antiviral Therapy, 2008, 13, 601-605.	0.6	26
41	Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies. Clinical Infectious Diseases, 2016, 63, 1373-1379.	2.9	25
42	Influence of Hepatitis C Virus Coinfection on Lipid Abnormalities in HIV-Positive Patients After Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 315-317.	0.9	24
43	Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-NaÃ¯ve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir. HIV Clinical Trials, 2012, 13, 245-255.	2.0	24
44	Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy. International Journal of Molecular Sciences, 2016, 17, 434.	1.8	24
45	Predictors of AIDS-Defining Events Among Advanced NaÃ¯ve Patients After HAART. HIV Clinical Trials, 2007, 8, 112-120.	2.0	22
46	Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort study. BMC Infectious Diseases, 2017, 17, 193.	1.3	22
47	Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. Human Genetics, 2022, 141, 147-173.	1.8	22
48	Lipid Abnormalities in HIV-Infected Patients Are Not Correlated With Lopinavir Plasma Concentrations. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 324-326.	0.9	21
49	Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens. Drug Safety, 2007, 30, 1161-1169.	1.4	21
50	No evidence of benefical effect of GB virus type C infection on the course of HIV infection. Aids, 2002, 16, 1430-1431.	1.0	21
51	Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy. Journal of Clinical Laboratory Analysis, 2001, 15, 43-46.	0.9	20
52	The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population. BMC Public Health, 2016, 16, 1146.	1.2	20
53	Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives. Pharmaceuticals, 2021, 14, 1272.	1.7	20
54	The evolving burden of HIV infection compared with other chronic diseases in northern Italy*. HIV Medicine, 2011, 12, 129-137.	1.0	19

#	Article	IF	Citations
55	The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study. Journal of Translational Medicine, 2015, 13, 89.	1.8	19
56	The impact of antiretroviral therapy on iron homeostasis and inflammation markers in HIV-infected patients with mild anemia. Journal of Translational Medicine, 2017, 15, 256.	1.8	19
57	A 2021 Update on Syphilis: Taking Stock from Pathogenesis to Vaccines. Pathogens, 2021, 10, 1364.	1.2	19
58	Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting. Health Policy, 2003, 65, 261-267.	1.4	18
59	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. Clinical Infectious Diseases, 2021, 73, 50-59.	2.9	18
60	Immune Correlates of Virological Response in HIV-Positive Patients after Highly Active Antiretroviral Therapy (HAART). Viral Immunology, 2004, 17, 279-286.	0.6	17
61	Influence of Folate Serum Concentration on Plasma Homocysteine Levels in HIV-Positive Patients Exposed to Protease Inhibitors Undergoing HAART. Annals of Nutrition and Metabolism, 2006, 50, 247-252.	1.0	17
62	Updated prevalence of genotypic resistance among HIV-1 positive patients naÃ¯ve to antiretroviral therapy: a single center analysis. Journal of Medical Virology, 2008, 80, 747-753.	2.5	17
63	Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection. Osteoporosis International, 2014, 25, 2263-2269.	1.3	17
64	Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. Journal of Antimicrobial Chemotherapy, 2018, 73, 1949-1954.	1.3	17
65	Omicron BA.2 Lineage, the â€œStealthâ€•Variant: Is It Truly a Silent Epidemic? A Literature Review. International Journal of Molecular Sciences, 2022, 23, 7315.	1.8	17
66	Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for mediumâ€“long-term all-cause mortality: a MASTER cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 3519-3527.	1.3	16
67	Severe COVID-19 in Hospitalized Carriers of Single CFTR Pathogenic Variants. Journal of Personalized Medicine, 2021, 11, 558.	1.1	16
68	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infectionâ€“Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study. Pathogens and Immunity, 2020, 5, 8.	1.4	16
69	Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients. Journal of Translational Medicine, 2012, 10, 94.	1.8	15
70	Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). International Journal of Epidemiology, 2017, 46, dyv192.	0.9	15
71	Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience. AIDS Research and Human Retroviruses, 2018, 34, 570-574.	0.5	15
72	Rhodococcus equi: pulmonary cavitation lesion in patient infected with HIV cured by levofloxacin and rifampicin. Aids, 2002, 16, 1440-1442.	1.0	15

#	Article	IF	Citations
73	Oesophagobronchial fistula caused by varicella zoster virus in a patient with AIDS: a unique case. Journal of Clinical Pathology, 2002, 55, 397-398.	1.0	15
74	Predictors of Clinical Progression among HIV-1â€“Positive Patients starting HAART with CD4⁺ T-cell Counts â‰¥200 cells/mm³. Antiviral Therapy, 2007, 12, 941-948.	0.6	15
75	First Italian Consensus Statement on Diagnosis, Prevention and Treatment of Cardiovascular Complications in HIV-infected Patients in the HAART Era (2006). Infection, 2007, 35, 134-142.	2.3	14
76	Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study. PLoS ONE, 2016, 11, e0154900.	1.1	14
77	Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive patients naÃ¯ve for anti-retrovirals. Clinical Microbiology and Infection, 2004, 10, 826-830.	2.8	13
78	Screening and Management of HIV-2-Infected Individuals in Northern Italy. AIDS Patient Care and STDs, 2008, 22, 489-494.	1.1	13
79	Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. Journal of the International AIDS Society, 2014, 17, 19808.	1.2	13
80	Detection of Clonal T Cell Populations with Closely Related T Cell Receptor Junctional Sequences in Persons at High Risk for Human Immunodeficiency Virus (HIV) Infection and in Patients Acutely Infected with HIV. Journal of Infectious Diseases, 1997, 175, 272-282.	1.9	12
81	Perinatally HIV-Infected Youths After Transition from Pediatric to Adult Care, a Single-Center Experience from Northern Italy. AIDS Research and Human Retroviruses, 2018, 34, 241-243.	0.5	12
82	Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015. BMC Infectious Diseases, 2018, 18, 285.	1.3	12
83	C9orf72 Intermediate Repeats Confer Genetic Risk for Severe COVID-19 Pneumonia Independently of Age. International Journal of Molecular Sciences, 2021, 22, 6991.	1.8	12
84	Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naÃ¯ve for lopinavir with limited exposure to previous protease inhibitors. Journal of Clinical Virology, 2006, 35, 414-419.	1.6	11
85	The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naÃ¯ve patients. Cytokine, 2020, 126, 154884.	1.4	11
86	Prevalence of Non-B HIV-1 Subtypes in North Italy and Analysis of Transmission Clusters Based on Sequence Data Analysis. Microorganisms, 2020, 8, 36.	1.6	11
87	Risk factors for myocardial infarction in HIV-positive patients. International Journal of STD and AIDS, 2005, 16, 14-18.	0.5	10
88	Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. International Journal of Antimicrobial Agents, 2007, 29, 185-190.	1.1	10
89	Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications. Epidemiology and Infection, 2010, 138, 1298-1307.	1.0	10
90	Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy). BMC Public Health, 2011, 11, 124.	1.2	10

#	Article	IF	Citations
91	Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 312-318.	0.9	10
92	Disengagement and reengagement of HIV continuum of care in a single center cohort in northern Italy. HIV Research and Clinical Practice, 2019, 20, 1-11.	1.1	10
93	Decrease in New Diagnosis of HIV/AIDS in the Two Years Period 2019-2020: Impact of COVID-19 Pandemic. Journal of Public Health Research, 2022, 11, jphr.2021.2256.	0.5	10
94	Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone. Digestive and Liver Disease, 2001, 33, 163-172.	0.4	9
95	No Evidence of Relation Between Peripheral Neuropathy and Presence of Hemochromatosis Gene Mutations in HIV-1-Positive Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 255-256.	0.9	8
96	Low prevalence of symptomatic thyroid diseases and thyroid cancers in HIV-infected patients. Scientific Reports, 2019, 9, 19459.	1.6	8
97	A COPD Case-Finding Program in a Large Cohort of HIV-Infected Persons. Respiratory Care, 2019, 64, 169-175.	0.8	8
98	Letter to the Editor on â€œBonafÃ¨ M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Revâ€• Cytokine and Growth Factor Reviews, 2020, 54, 1-2.	3.2	8
99	Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy. Journal of Clinical Laboratory Analysis, 2002, 16, 76-78.	0.9	7
100	SENV Infection in HIV-Positive Patients: Prevalence, Subtype Characterization, and Impact on HIV Disease Progression. AIDS Research and Human Retroviruses, 2003, 19, 1079-1082.	0.5	7
101	Lopinavir Plasma Levels in Salvage Regimes by a Population of Highly Active Antiretroviral Therapy-Treated HIV-1â€“Positive Patients. AIDS Patient Care and STDs, 2004, 18, 629-634.	1.1	7
102	Breast cancer among human immunodeficiency virus (HIV)-infected patients: the experience in Brescia, Northern Italy. Brazilian Journal of Infectious Diseases, 2012, 16, 396-397.	0.3	7
103	Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults. Expert Review of Anti-Infective Therapy, 2018, 16, 877-887.	2.0	7
104	Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: Prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. Journal of Medical Virology, 2004, 74, 29-33.	2.5	6
105	Lung cancer in HIV-infected patients: the experience in Brescia from 1999 to 2009. International Journal of STD and AIDS, 2012, 23, 753-755.	0.5	6
106	SARS-CoV-2 Infection and Vaccination Coverage among Fragile Populations in a Local Health Area of Northern Italy. Life, 2022, 12, 1009.	1.1	6
107	Longâ€term benefit of genotypicâ€guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients. Journal of Clinical Laboratory Analysis, 2001, 15, 127-130.	0.9	5
108	Predictors of Long-Term Immunological Outcome in Rebounding Patients on Protease Inhibitor-Based HAART After Initial Successful Virologic Suppression: Implications for Timing to Switch. HIV Clinical Trials, 2003, 4, 311-323.	2.0	5

#	Article	IF	Citations
109	Adherence And Plasma Drug Concentrations Are Predictors of Confirmed Virologic Response after 24-Week Salvage Highly Active Antiretroviral Therapy. AIDS Patient Care and STDs, 2007, 21, 92-99.	1.1	5
110	Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide. Aids, 2007, 21, 1388-1389.	1.0	5
111	The Impact of Gender and Anchor Drugs on TDF Renal Toxicity. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, e11-e12.	0.9	5
112	The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study. Infectious Agents and Cancer, 2015, 10, 34.	1.2	5
113	Evaluation of Boosted and Unboosted Atazanavir Plasma Concentration in HIV Infected Patients. Current HIV Research, 2014, 11, 642-646.	0.2	5
114	Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine ATV/r in Patients with Preserved Renal Function. Open AIDS Journal, 2016, 10, 136-143.	0.1	5
115	Evidence of HIV-2 Infection in Northern Italy. Infection, 2001, 29, 362-363.	2.3	4
116	HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations. Journal of Antimicrobial Chemotherapy, 2003, 52, 776-781.	1.3	4
117	HIV-1 Resistance to Dideoxynucleoside Reverse Transcriptase Inhibitors: Genotypic???Phenotypic Correlations. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 1104-1107.	0.9	4
118	Modifications in SENV DNA Detection and/or SENV Subtype Determination over a Prospective Follow-Up in a Cohort of HIV-Positive Patients: Is This a Moving Target?. Intervirology, 2004, 47, 350-354.	1.2	3
119	HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir-containing regimens. Journal of Clinical Laboratory Analysis, 2005, 19, 26-29.	0.9	3
120	Osteoporosis in Human Immunodeficiency Virus Patients â€“ An Emerging Clinical Concern. European Endocrinology, 2010, 10, 79.	0.8	3
121	Modulation of Regulatory T-Cell Subsets in Very Long-Term Treated Aviremic HIV+ Patients and Untreated Viremic Patients. Open AIDS Journal, 2014, 8, 1-6.	0.1	3
122	Eye instability induced by vestibular stimulation in rabbits. NeuroReport, 2001, 12, 1847-1850.	0.6	2
123	Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort. Clinical Microbiology and Infection, 2015, 21, 386.e1-386.e9.	2.8	2
124	Peripheral loss of regulatory T cells and polyautoimmunity in an HIV-infected patient. International Journal of STD and AIDS, 2018, 29, 1345-1347.	0.5	2
125	Symptoms and quality of life in HIV-infected patients with benign prostatic hyperplasia are improved by the consumption of a newly developed whole tomato-based food supplement. A phase II prospective, randomized double-blinded, placebo-controlled study. Journal of Functional Foods, 2021, 82, 104495.	1.6	2
126	Psychological and Emotional Impact of COVID-19 Pandemic on People Living with Chronic Disease: HIV and Cancer. AIDS and Behavior, 2022, 26, 2920-2930.	1.4	2

#	Article	IF	Citations
127	Potential role of SEN virus on liver enzyme abnormalities in patients positive for hepatitis C virus with or without HIV infection. European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24, 436-437.	1.3	1
128	Reply to van der Pas et al. Clinical Infectious Diseases, 2011, 53, 614-615.	2.9	1
129	Characteristics and Outcome of a Cohort of HIV-1 Non-B Subtypeâ€“Infected Patients After a 10-Year Follow-up Period: A Single Centre Experience. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, e23-e24.	0.9	1
130	Prognostic role of inflammatory biomarkers in HIVâ€infected patients with a first diagnosis of hepatocellular carcinoma: A singleâ€center study. Journal of Medical Virology, 2019, 91, 241-248.	2.5	1
131	Presence of V72I, G123S and R127K Integrase Inhibitor polymorphisms could reduce ART effectiveness: a retrospective longitudinal study. HIV Research and Clinical Practice, 2020, 21, 24-33.	1.1	1
132	An HIV elite controller patient carrying the homozygous H63D variant in the homeostatic iron regulator gene. Medicine (United States), 2021, 100, e27732.	0.4	1
133	IMMUNOLOGICAL EVOLUTION OF A COHORT OF HIV-2 INFECTED PATIENTS: PECULIARITIES OF AN UNDERESTIMATED INFECTION. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022016.	0.5	1
134	Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort. BMC Infectious Diseases, 2017, 17, 212.	1.3	0
135	HIV-associated asymmetric lipodystrophy syndrome. Revista Clinica Espanola, 2004, 204, 177-177.	0.2	0
136	Influence of Hepatitis C Virus Coinfection on Lipid Abnormalities in HIV-Positive Patients After Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 315-317.	0.9	0
137	Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy. Journal of Clinical Medicine, 2022, 11, 471.	1.0	0
138	An exploratory pilot study on the involvement of APOE, HFE, C9ORF72 variants and comorbidities in neurocognitive and physical performance in a group of HIV-infected people. Metabolic Brain Disease, 2022, , 1.	1.4	0
139	126. Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection and Vaccination. Open Forum Infectious Diseases, 2021, 8, S77-S77.	0.4	0